vesting schedule

Cue Biopharma grants inducement equity to new President and CEO Dr. Shao-Lee Lin and six employees under Nasdaq rules, signaling leadership transition and growth strategy.

Absci grants 276,200 non-statutory stock options at $4.92/share to newly hired employee as employment inducement under Nasdaq listing rules.

Zentalis Pharmaceuticals granted 26,000 stock options to new employee at $4.09 exercise price under inducement plan provisions.

NewAmsterdam Pharma approved inducement grants totaling 50,400 options and 15,400 RSUs to five new non-executive employees under Nasdaq compliance rules.

Xilio Therapeutics granted stock options for 3,257 shares to two new employees at $8.48 exercise price, reflecting typical equity compensation practices for biotech hiring.

Inhibikase Therapeutics grants 685,718 stock options at $1.68/share to five new hires under Nasdaq inducement plan with ten-year terms.

Kura Oncology granted 153,750 stock options at $8.34/share to six new employees under Nasdaq Rule 5635(c)(4), valued at approximately $1.28 million, with standard four-year vesting.

NewAmsterdam Pharma grants 15,000 options and 3,200 RSUs to two new executives, complying with Nasdaq listing regulations.

Vor Bio awarded stock options and RSUs to nine newly hired employees as employment inducements, with options exercisable at $17.39 per share over a 10-year term.

Cytokinetics granted inducement stock options and RSUs to five new employees hired in early 2026, using Nasdaq listing rule 5635(c)(4) to compensate talent.

Elutia grants 460,000 non-qualified stock options to three new employees at $1.09 exercise price with four-year vesting under Nasdaq inducement rules.

Tango Therapeutics grants new employee 367,500 stock options and 60,000 RSUs valued at $11.94 exercise price under inducement plan.

Rent the Runway grants Executive Chair Fonseca 802K RSUs as an inducement award, vesting over three years to retain key talent.

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.

CAMP4 Therapeutics granted 8,000 stock options to a new employee at $3.85/share exercise price, using standard four-year vesting under Nasdaq rules for talent attraction.

Elicio Therapeutics granted 30,300 stock options at $8.59 per share to a new employee on February 17, 2026, vesting over four years.

BridgeBio Pharma awarded 76,701 restricted stock units to 34 new employees as inducement grants under Nasdaq rules, vesting over four years with continued employment.